ADRX SEC Filings, Earnings & Splits

LAV Biosciences Fund V, L.P., LAV Fund VI, L.P., LAV Fund VI Opportunities, L.P., and Yi Shi filed a joint Schedule 13G regarding their passive ownership of ADARx Pharmaceuticals common stock. The filing includes a joint filing agreement as an exhibit.

SR One Capital Management and affiliated funds filed a joint Schedule 13D regarding their ownership of ADARx Pharmaceuticals common stock, executed via power of attorney on October 5, 2026.

OrbiMed entities filed a joint filing agreement as part of a Schedule 13D regarding their position in ADARx Pharmaceuticals common stock. The agreement confirms the filing is made jointly on behalf of the OrbiMed funds.

A Schedule 13G was filed indicating a passive ownership position in ADARx Pharmaceuticals, Inc. (ADRX). The filing reflects a holder's beneficial ownership stake of 5% or more, with no stated intent to influence company control.

ADARx Pharmaceuticals, Inc. priced its initial public offering of 26,250,000 shares of common stock at $17.00 per share, with an underwriters' option to purchase up to an additional 3,937,500 shares. The offering is expected to close on September 28, 2026, and the stock will list on Nasdaq under the symbol ADRX.

ADARx Pharmaceuticals closed its initial public offering (IPO) of 26,250,000 shares at $17.00 per share, generating gross proceeds of approximately $446.3 million, and concurrently closed a private placement with AbbVie Inc. for 5,255,542 shares at the same price, generating approximately $89.3 million in gross proceeds.

ADARx Pharmaceuticals, Inc. filed an EFFECT notice with the SEC, indicating that a previously filed registration statement has become effective.